Detection of Δ9-Tetrahydrocannabinol in Exhaled Breath Collected from Cannabis Users O Beck, S Sandqvist, I Dubbelboer, J Franck Journal of Analytical Toxicology 35 (8), 541-544, 2011 | 98 | 2011 |
Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC–ESI–MS/MS IR Dubbelboer, A Pohanka, R Said, S Rosenborg, O Beck Therapeutic drug monitoring 34 (2), 134-142, 2012 | 58 | 2012 |
Liver cancer cell lines treated with doxorubicin under normoxia and hypoxia: cell viability and oncologic protein profile IR Dubbelboer, N Pavlovic, F Heindryckx, E Sjögren, H Lennernäs Cancers 11 (7), 1024, 2019 | 53 | 2019 |
Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems IR Dubbelboer, E Lilienberg, E Ahnfelt, E Sjögren, N Axén, H Lennernäs Therapeutic delivery 5 (4), 447-466, 2014 | 43 | 2014 |
In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma E Lilienberg, IR Dubbelboer, A Karalli, R Axelsson, TB Brismar, ... Molecular pharmaceutics 14 (2), 448-458, 2017 | 40 | 2017 |
Physiological properties, composition and structural profiling of porcine gastrointestinal mucus V Barmpatsalou, IR Dubbelboer, A Rodler, M Jacobson, E Karlsson, ... European Journal of Pharmaceutics and Biopharmaceutics 169, 156-167, 2021 | 30 | 2021 |
A model-based approach to assessing the importance of intracellular binding sites in doxorubicin disposition IR Dubbelboer, E Lilienberg, E Sjögren, H Lennernas Molecular pharmaceutics 14 (3), 686-698, 2017 | 26 | 2017 |
Gastrointestinal mucus in dog: Physiological characteristics, composition, and structural properties IR Dubbelboer, V Barmpatsalou, A Rodler, E Karlsson, SF Nunes, ... European Journal of Pharmaceutics and Biopharmaceutics 173, 92-102, 2022 | 20 | 2022 |
Rat intestinal drug permeability: A status report and summary of repeated determinations IR Dubbelboer, D Dahlgren, E Sjögren, H Lennernäs European Journal of Pharmaceutics and Biopharmaceutics 142, 364-376, 2019 | 17 | 2019 |
The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs IR Dubbelboer, E Lilienberg, M Hedeland, U Bondesson, ... Molecular Pharmaceutics 11 (4), 1301-1313, 2014 | 14 | 2014 |
Physiological based pharmacokinetic and biopharmaceutics modelling of subcutaneously administered compounds–An overview of in silico models IR Dubbelboer, E Sjögren International Journal of Pharmaceutics 621, 121808, 2022 | 12 | 2022 |
Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment IR Dubbelboer, E Sjögren, H Lennernäs The AAPS Journal 20, 1-11, 2018 | 11 | 2018 |
Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs E Lilienberg, IR Dubbelboer, E Sjögren, H Lennernäs Journal of Pharmacy and Pharmacology 69 (2), 135-142, 2017 | 7 | 2017 |
Overview of authorized drug products for subcutaneous administration: pharmaceutical, therapeutic, and physicochemical properties IR Dubbelboer, E Sjögren European Journal of Pharmaceutical Sciences 173, 106181, 2022 | 5 | 2022 |
Biopharmaceutical investigations of doxorubicin formulations used in liver cancer treatment: Studies in healthy pigs and liver cancer patients, combined with pharmacokinetic … IR Dubbelboer Acta Universitatis Upsaliensis, 2017 | 5 | 2017 |
Development of a canine artificial colonic mucus model for drug diffusion studies V Barmpatsalou, M Tjakra, L Li, IR Dubbelboer, E Karlsson, BP Lomstein, ... European Journal of Pharmaceutical Sciences 194, 106702, 2024 | 2 | 2024 |
Systematic review of physiologically based kinetic lactation models for transfer of xenobiotic compounds to milk IR Dubbelboer, L Le Roux-Pullen, R Gehring Toxicology and Applied Pharmacology 467, 116495, 2023 | 2 | 2023 |
Reply to" Comment on'In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma'" IR Dubbelboer, E Lilienberg, A Karalli, R Axelsson, TB Brismar, ... Molecular pharmaceutics 15 (1), 336-340, 2018 | 1 | 2018 |
Benefits of combining supersaturating and solubilizing formulations–Is two better than one? C Alvebratt, F Karlén, M Åhlén, K Edueng, I Dubbelboer, CAS Bergström International Journal of Pharmaceutics 663, 124437, 2024 | | 2024 |
In vitro screening model for compound interactions with human and dairy animal BCRP orthologs. J Van den Heuvel, NB Jonis, T Scheer-Weijers, IR Dubbelboer, ... Journal of Veterinary Pharmacology and Therapeutics, 2024 | | 2024 |